Navigation Links
Healthcare Industry Leader Virginia Rybski Remembered
Date:5/13/2013

SCOTTSDALE, Ariz., May 13, 2013 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company focused on tissue regeneration, announced today that CEO Virginia Rybski lost her battle with pancreatic cancer.  Virginia was compassionately dedicated to her family, colleagues, patients and faith.

(Photo:  http://photos.prnewswire.com/prnh/20130513/LA13153)

(Logo:  http://photos.prnewswire.com/prnh/20120109/LA31405LOGO)

"We celebrate the privilege to have worked with such a talented leader, who was the driving force behind Regenesis' success," said John Voris , Chairman of the Board of Directors.  "Virginia's legacy includes a capable and dedicated management team that remains intact.  They are committed to achieving her vision of reaching patients in need of pain relief with the Provant® Therapy System."  

Ms. Rybski served Regenesis most recently as President, Chief Executive Officer and Board Director.  She combined 35 years experience founding and building emerging bioscience companies, by developing and commercializing numerous advanced-technology healthcare products.  Virginia earned a Bachelor of Arts in Molecular Biology from the University of North Carolina, and a Masters in Hospital Administration from the University of Phoenix.  She served on the Board of Directors for AdvaMed, the advanced medical technology association, as well as serving on the Emerging Growth Company Council, the Payment Advisory Work Group, and the Wound Sector Group.  She also served on the Board of Directors for AZBIO, the Arizona biotechnology and medical device association.

Virginia is survived by her husband Tom, and daughters Savannah and Olivia.  Her family provided the opportunity to support pancreatic research, through the Pancreatic Cancer Action Network at https://netcommunity.pancan.org/sslpage.aspx?pid=218

Regenesis will soon make an announcement regarding the CEO succession plan.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products.  Regenesis developed, patented, and now markets the Provant Therapy System.  Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and outpatient clinics.

About the Provant® Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

Contact: Regenesis Biomedical, Inc.
Scott Robey , Vice President Marketing
www.regenesisbio.com
480-970-4970 phone


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CitiusTechs BI-Clinical Platform for Healthcare BI & Analytics Receives NCQA HEDIS Certification
2. Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference
3. Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
4. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
5. Healthcare Corporation of America Sets Date for Release of its First-Quarter Results and Conference Call
6. Bayer Employee Named Rising Star by Healthcare Businesswomens Association
7. Maxim Healthcare Services Names National Caregiver of the Year Winner
8. Allied Healthcare Products Reports Loss On Depressed Sales
9. BidMed Awarded Equipment Liquidation and Related Services Agreement with the Premier Healthcare Alliance
10. Millennium HealthCare Signs Exclusive Distribution Agreement with Heart Smart Inc.
11. Cynosure to Present at UBS Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):